ATE383170T1 - Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c - Google Patents

Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c

Info

Publication number
ATE383170T1
ATE383170T1 AT02759107T AT02759107T ATE383170T1 AT E383170 T1 ATE383170 T1 AT E383170T1 AT 02759107 T AT02759107 T AT 02759107T AT 02759107 T AT02759107 T AT 02759107T AT E383170 T1 ATE383170 T1 AT E383170T1
Authority
AT
Austria
Prior art keywords
infection
cell
inhibit
hcv
hcv infection
Prior art date
Application number
AT02759107T
Other languages
English (en)
Inventor
William Olson
Paul Maddon
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE383170T1 publication Critical patent/ATE383170T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02759107T 2001-06-26 2002-06-26 Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c ATE383170T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/891,894 US20030013081A1 (en) 2001-06-26 2001-06-26 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection

Publications (1)

Publication Number Publication Date
ATE383170T1 true ATE383170T1 (de) 2008-01-15

Family

ID=25399013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759107T ATE383170T1 (de) 2001-06-26 2002-06-26 Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c

Country Status (8)

Country Link
US (1) US20030013081A1 (de)
EP (2) EP1411980B1 (de)
JP (1) JP2005521628A (de)
AT (1) ATE383170T1 (de)
CA (1) CA2452049A1 (de)
DE (1) DE60224541T2 (de)
ES (1) ES2296985T3 (de)
WO (1) WO2003000024A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339830A2 (de) * 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Methode zur modulation der bindungsaktivität eines neuen icam-3 bindenden rezeptors in sinusoidalen endothelzellen aus leber und lymphknoten
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
AU2003269389A1 (en) * 2002-09-20 2004-04-08 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
US20050281828A1 (en) * 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
JP2006521387A (ja) * 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
CN113150076B (zh) * 2021-03-03 2022-05-31 天津医科大学 环五肽的合成方法及其在抗丙肝药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ES2171401T3 (es) 1986-05-20 2002-09-16 Gen Hospital Corp Metodos para estudios farmacocineticos de la expresion de insulina con un mamifero transgenico no-humano.
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
NZ243908A (en) 1991-08-16 1994-12-22 Beth Israel Hospital Assn Mutant l3t4 protein which facilitates hiv infection; transgenic mouse
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US5912411A (en) 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
EP0701127B1 (de) 1994-03-18 2001-05-23 Japan Poliomyelitis Research Institute Verfahren zum testen der neurotoxizität eines poliovirusimpfstoffes
EP0690452A3 (de) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Elektrisch löschbarer Speicher und Löschverfahren
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US6018098A (en) 1995-06-16 2000-01-25 Thomas Jefferson University In vivo and in vitro model of cutaneous photoaging
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
US5894078A (en) 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
US6025539A (en) 1996-04-09 2000-02-15 Mayo Foundation For Medical Education And Research IL-5 transgenic mouse
US5981829A (en) 1996-05-08 1999-11-09 Uab Research Foundation ΔNur77 transgenic mouse
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
JP4198882B2 (ja) 1997-10-06 2008-12-17 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃ型肝炎レセプタータンパク質ｃｄ８１
EP1046651A1 (de) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen

Also Published As

Publication number Publication date
EP1411980B1 (de) 2008-01-09
EP1411980A4 (de) 2005-06-29
EP1411980A2 (de) 2004-04-28
CA2452049A1 (en) 2003-01-03
DE60224541T2 (de) 2008-12-24
EP1946770A1 (de) 2008-07-23
DE60224541D1 (de) 2008-02-21
US20030013081A1 (en) 2003-01-16
WO2003000024A2 (en) 2003-01-03
WO2003000024A3 (en) 2003-07-31
ES2296985T3 (es) 2008-05-01
JP2005521628A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
ATE553201T1 (de) Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel
EA200300023A1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
EA200700243A1 (ru) Способы лечения гепатита с
DE69435155D1 (de) Zusuammensetzungen zur Behandlung von Krebs mittels Viren
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DK0637342T3 (da) Fremgangsmåde til typebestemmelse af HCV-isolater
WO2001059457A3 (en) Assay for detection of viral fusion inhibitors
ATE318176T1 (de) Verfahren zur entfernung von hiv und anderen viren aus blut
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
WO2005000308A3 (en) Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
ATE281647T1 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
WO2002055025A3 (en) Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection
BR9304352A (pt) Processo para a preparaçao de catalisador do tipo ziegler-natta com suporte granular e catalisador
DE60224541D1 (de) Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c
ATE309540T1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
EP1080040A4 (de) Verfahren zur reinigung von wasser
WO2003040726A3 (en) Screening for hepatitis c virus entry inhibitors
EP1709178A4 (de) Verfahren und verbindungen zur veränderung der hepatitisviruslast
SE0302652D0 (sv) Attachment of cells to surfaces
ATE286938T1 (de) Phosphorverbindungen als stabilisatoren
DE60335564D1 (de) Antiinfektiöse mittel
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties